Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Sep 1, 2012

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

CROs and CMOs Have Cause to Celebrate

Annual survey shows strong growth for service providers and promises to continue into 2013. This article is part of a special issue on outsourcing.
Aug 1, 2012

Annual survey shows strong growth for service providers and promises to continue into 2013.

Channeling Steve Jobs

Service providers must focus on delivering a superior customer experience.
May 2, 2012

Service providers must focus on delivering a superior customer experience.

Channeling Steve Jobs

Service providers must focus on delivering a superior customer experience.
May 1, 2012

Service providers must focus on delivering a superior customer experience.

CMOs Face a Kodak Moment

The evolving bio/pharmaceutical business model poses risk for CMOs.
Apr 4, 2012

The evolving bio/pharmaceutical business model poses risk for CMOs.

CMOs Face a Kodak Moment

The evolving bio/pharmaceutical business model poses risk for CMOs.
Mar 2, 2012

The evolving bio/pharmaceutical business model poses risk for CMOs.

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Feb 1, 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

Troublesome Signs for Bio/Pharmaceutical R&D

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future
Jan 12, 2012

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Jan 2, 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here